Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483894 | 0.87 | HTR3E (0.56) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL28599511 | 0.85 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL29656856 | 0.85 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL2925759 | 0.81 | HTR3E (0.68) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL28129519 | 0.81 | HTR3E (0.68) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL19850677 | 0.80 | HTR3E (0.45) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL23968199 | 0.80 | MAPKAPK2 (0.57) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL13734536 | 0.80 | DGAT1 (0.55) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL28218775 | 0.79 | ADRB1 (0.65) | ADRB1RAB9AMAPTKMT2ADRD2 | |
| SCHEMBL4765493 | 0.79 | MAPT (0.56) | RAB9AMAPTKMT2AL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | claimed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| CN-108137518-A | As 6 inhibitor of histone deacetylase 1,3,4- oxadiazole derivatives compound and include its pharmaceutical composition | 株式会社钟根堂 | 2018-06-08 | — | — | CN | disclosed |
| WO-2012042227-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PLANTS | PENINSULA COLLEGE OF MEDICINE AND DENTISTRY, UNIVERSITY OF EXETER (GB) | 2012-04-05 | — | — | WO | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | HTR3E 124/4885HTR3B 79/4885ADRB1 274/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | HTR3E 3089/4885HTR3B 1799/4885ADRB1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.